Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Remimazolam With Flumazenil vs. Propofol During RFCA for Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patient, age 20-75 years, scheduled for radiofrequency catheter ablation of atrial fibrillation under general anesthesia~Exclusion Criteria:~* Patients who are not alert before procedure~* Hemodynamicaly unstable patients before procedure~* Patients with history of adverse reaction of allergic reaction to study drugs~* Patients who are anticipated to be unable to remove supraglottic airway or endotracheal tube due to severe dyspnea or need for mechanical ventilatory support~* Use of sedatives (anxiolytics, psychoactive medication, antidepressants, hypnotics) within 24 h~* Known galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption~* Severe hepatic or renal dysfunction~* Alcohol or drug dependence~* Organic brain disorder~* Spinal or cerebellar ataxia~* Acute narrow-angle glaucoma~* Patients with shock or coma~* Pregnant or lactating women~* Patients with hypersensitive to beans or peanut~* Patients who refuse to participate

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Remimazolam with flumazenil (Type: EXPERIMENTAL): Patients allocated to remimazolam with flumazenil group receives remimazolam as the main anesthetics during general anesthesia and then flumazenil administration at the end of anesthesia. Remifentanil continuous infusion can be used for hemodynamic stability and analgesia.
- Propofol total intravenous anesthesia (Type: ACTIVE_COMPARATOR): Patients allocated to propofol total intravenous anesthesia group receives propofol as the main anesthetics during general anesthesia until the end of anesthesia. Remifentanil continuous infusion can be used for hemodynamic stability and analgesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).